作者: Caroline Uhler , Adityanarayanan Radhakrishnan , Karren Dai Yang , G. V. Shivashankar , G. V. Shivashankar
DOI: 10.1038/S41467-021-21056-Z
关键词:
摘要: Given the severity of the SARS-CoV-2 pandemic, a major challenge is to rapidly repurpose existing approved drugs for clinical interventions. While a number of data-driven and experimental approaches have been suggested in the context of drug repurposing, a platform that systematically integrates available transcriptomic, proteomic and structural data is missing. More importantly, given that SARS-CoV-2 pathogenicity is highly age-dependent, it is critical to integrate aging signatures into drug discovery platforms. We here take …